The pharmacokinetics of metformin therapy in patients with chronic kidney disease stage 4 (CKD-4) were studied using data from the largest Phase I consecutive cohort trial yet performed in this population. Eighteen metformin-naïve men and women with Type 2 Diabetes and creatinine clearance (CrCl) in the range 18-49 mL/min (eGFR 15-29 mL/min/1.73 m 2 ) were allocated to daily immediate-release metformin of 250 mg, 500 mg, or 1000 mg. A first-dose profile and trough concentrations for 4 weeks were taken on all patients. Pharmacokinetic (PK) parameters were estimated by fitting a first-order compartment model with absorption in a peripheral compartment to concentrations measured 24 hours post-first dose. Single-dose PK parameters time to maximum concentration (t max ) and maximum concentration (C max ) were consistent with previous observations in patients with normal renal function (healthy and diabetic), as was the association between CrCl and apparent total oral clearance (Cl/F). However, patients with a CrCl below 32 mL/min had trough concentrations that were consistently above the steady-state minimum implied by the population PK model. This suggests the model may not apply to patients with CrCl below 32 mL/min. Metformin in doses of 500-1000 mg/day could be taken by CKD-4 patients. However, the single-compartment model breaks down as CrCl declines below 32 mL/min suggesting that metformin levels should be monitored regularly in progressive stage 4 CKD.
largely based on case reports 3 and the fact that phenformin, a precursor of metformin of the same therapeutic class but with different mechanisms of action, undoubtedly did cause significant rates of lactic acidosis. 4 Many large observational studies have failed to find evidence of metformin-associated lactic acidosis. Scale Patients with CKD-5 were excluded from our study. Inzucchi et al 8 and Hung et al 9 called for more studies to investigate the safety and therapeutic effect of metformin therapy in patients with CKD.
Despite the literature cited above, use of metformin in this population remains controversial 10, 11 and contrary to national guidelines in many jurisdictions. 8 However, small studies 12 and ones reporting only steady-state concentrations 13, 14 show that therapeutic levels should be achievable. A simulation study by 
| MATERIALS AND METHODS

| Subjects and protocol
Eligibility criteria and study protocol are described elsewhere. 16 Briefly, metformin-naïve men and women aged 30-75 years weighing <160 kg with T2DM were eligible for this study if their diabetes had been diagnosed at least 2 years prior to screening (in accordance A consecutive cohort design was chosen because this was a safety and tolerability Phase I study (this group had not been prescribed metformin) with pharmacokinetic evaluation on different doses. The study size was chosen to be consistent with other pharmacokinetic studies in the nonrenal population; no a priori power calculation was performed.
The New Zealand Health and Disability Ethics Committee approved this study (reference number NTX/11/12/112) and all participants gave written informed consent prior to enrolment. Safety monitoring (including for signs of acidosis) was done by an independent physician.
| Outcomes
The primary safety outcome of the trial was the development of acidosis assessed via fasting levels of venous lactate, bicarbonate, and pH. This was reported on in Dissanayake et al. 16 In this study we assess additional outcomes, namely, single-and repeat-dose fasting serum metformin concentrations. Each participant's first dose was taken at Visit 2 (Day 4) after baseline serum metformin levels were taken. Metformin levels were then taken at 2, 4, 6, 8, and 24 hours (Visit 3) post-first dose. Pharmacokinetic parameters were determined using these concentrations which totaled 102 observations (5-6 per patient over a 24-hour period). Pre-dose concentrations were taken at all subsequent visits (Visits 4-8). Patients were instructed to fast overnight and present for their laboratory test in the morning prior to taking that day's dose. 
| Other measures
where D is the dose in mg, t is time postdose in hours, and k a and K are the absorption and elimination rate constants, respectively. 
Confidence intervals for average c min,ss , c avg,ss , and c max,ss and average values of each under specific baseline CrCls were formed by applying the delta method to the parameter estimates produced by models in Equations (1) and (2).
| Observed trough concentrations
Observed trough concentrations were compared with confidence intervals for average c min,ss , c avg,ss , and c max,ss implied by the popPK model fitted to the single-dose data (entire data set). The intervals were computed by applying the delta method to the variance-covariance matrix of the estimated fixed effects regression coefficients and applying the relevant quantiles of the standard normal distribution.
They represent a 95% confidence interval for the average value of the response for a given set of values for the explanatory variables.
It is possible that on some visits some patients violated protocol and took metformin before having their predose blood test. These would be suspected if one or two observed trough-level concentrations per patient were within the 95% confidence interval for the steady-state maximum concentrations while the patient's other observations were within the confidence interval for the minimum. Values meeting these criteria were identified and labeled in plots. However, because there is no independent way to assess whether or not this occurred no data points were removed from any statistical analyses. It is likely therefore that the within-and between-subjects variances are overestimated (leading to wider confidence intervals) in regression models for the observed trough concentrations. This is a conservative approach.
In exploratory analysis, log concentrations were modeled as a function of dose, CrCl, and BMI. A linear mixed effects model with random intercepts for patient was used to account for repeat observations on each patient. Starting with a model with all two-way interactions, nonsignificant terms were eliminated sequentially beginning with interactions. All but the main effects of CrCl and dose were significant and only these two explanatory variables were retained.
| Metformin assay
A high-performance liquid chromatographic assay was used to measure metformin concentration in plasma. This was described and validated by Zhang et al 30 The limit of quantification was approximately 20 μg/L and the coefficient of variation estimated by Zhang et al 30 from intra-and interday assay variance was <9.0%.
| Materials
We used generic metformin (active ingredient metformin hydrochloride) which was prescribed by the conducting clinician to each patient. Note that the C max and t max values reported in Dissanayake et al 16 (Table 2) are empirical medians, whereas the values in Table 2 in this article are estimates (with confidence intervals) from the compartment model.
| Repeat dose
Trough concentrations were observed 24 hours postdose, the first observation being 7 days (24 hours) after commencing medication.
The mean elimination half-life ðt AIC and BIC for this model were −48.9 and −30.6, while for the model without CrCl they were, respectively, −57.0 and −38.7. As 'smaller is better', these criteria preferred the model without CrCl.
Nevertheless, estimates of k a and K from the two models were quite similar (Table A3 ) and residual diagnostics indicated the CrCl model was still a good fit, hence we proceeded to use it to estimate dose recommendations for various levels of CrCl (Section 3.3.3).
To explore the relationship between CrCl and trough concentrations, we split the study cohort into two groups by comparing observed trough levels at visits 3-6 with steady-state minimum concentrations 
| Dose recommendations
The popPK compartment model with CrCl can be used to estimate repeat-dose peak concentrations for a given dose and baseline CrCl.
They may be useful in determining the dose required to obtain a given steady-state concentration for a patient with known baseline
CrCl. Estimates are given for CrCl 30-50 mL/min in 
| DISCUSSION AND CONCLUSIONS
We conducted the largest consecutive dose-escalating study of metformin in patients with metformin-naïve T2DM and CKD-4 to date.
Eighteen patients with eGFR < 30 mL/min/1.73 m 2 were allocated to 1 of 3 dose groups: 250 mg/day, 500 mg/day, and 1000 mg/day.
Administration was oral by immediate-release tablet. We fitted a single-compartment popPK model to 102 concentrations (5-6 per patient) post-first dose. Bardin et al 27 and Doung et al 15 (instant release formulation) also modeled metformin concentration in T A B L E 3 Estimated average repeat-dose serum concentrations (mg/L) and 95 percent confidence intervals for the study cohort based on the popPK model in F I G U R E 2 Repeat-dose serum metformin concentrations recorded at Visits 3-6 for each dose group 24 hours postdose (trough levels) for those patients with more than one observation above the upper limit of the 95% CI for the mean of the steady-state trough level (patients 1, 2, 4, 6, 7, 9, 10, 14, 16, 17, and 19). Number labels and lines indicate observed value; from top to bottom, ribbons show the 95% CIs for the means of the theoretical steady-state maximum, mean, and trough concentrations, respectively, for a population meeting eligibility criteria with average Cl/F and k a . Note that different vertical scales are used in each panel to allow the plots to be easily read F I G U R E 3 Repeat-dose serum metformin concentrations recorded at Visits 3-6 for each dose group 24 hours post-dose (trough levels) for those patients with no more than one observation above the upper limit of the 95% CI for the mean of the steady-state trough level (patients 3, 5, 8, 11, 12, 13, and 18). Number labels and lines indicate observed value; from top to bottom, ribbons show the 95% CIs for the means of the theoretical steady-state maximum, mean, and trough concentrations, respectively, for a population meeting eligibility criteria with average Cl/F and k a . Note that different vertical scales are used in each panel to allow the plots to be easily read patients with T2DM and impaired renal function and similarly found a single-compartment model to be appropriate.
The fixed effects parameters in our single-compartment model were the absorption and elimination rate constants (k a and K) and the apparent clearance (Cl/F). Fixed effect estimates for AUC 0-∞ , t max , C max , and the absorption and elimination half-lives (t ka 1=2 and t K 1=2 ) were derived using the delta method (Table 2) . Patient-specific random intercepts were added for Cl/F and k a to account for the repeated measurements on patients.
| Single-dose pharmacokinetics
Time to maximum concentration (t max ) and maximum concentration at t max (C max ) were consistent with previous observations in patients with normal renal function (healthy and diabetic). Our estimate for mean Sambol et al 12 give means from two groups with chronic renal impairment after an oral dose of 850 mg. Renal function in their patients was similar to ours (moderate impairment group: CrCl 31-60 mL/min, n = 5; severe impairment group: CrCl 10-30 mL/min, n = 6). Mean t max s were 3.75 hours and 4.01 hours; the latter being larger than the upper limit of our confidence interval but comparable with empirical median t max s observed in our 500 mg and 1000 mg groups (4.0 hours in both; see ref. 16 Table 2 ). Sambol et al's 12 mean C max s were 4.12 mg/L and 3.93 mg/L, higher than our modeled (see above) and empirical median C max s for comparable doses (500 mg:
1.13 mg/L; 1000 mg: 2.28 mg/L). It remains unclear why Sambol et al 12 observed higher C max s. However, due to small group sizes and differences in study cohorts, sampling variation should not be ruled out. Metformin naïveté was not stipulated and, unlike our cohort, 7 of their moderate or severe patients were nondiabetic. Moreover, mean ages were 45.5 years (SD: 6.1; moderate) and 38.3 (SD: 13.6;
severe) compared with a mean of 64.1 years (SD: 7.9) for our 500 mg and 1000 mg patients.
Tucker et al 32 give means from 2 groups with T2DM, but better renal function after a single 1000 mg oral dose ("Group II": CrCl 85-120 mL/min n = 4; "Group III": CrCl 51-116 mL/min n = 8 
| Dose recommendations
It remains unclear what the therapeutic range of metformin is in patients with impaired renal function. Frid et al 14 
| Conclusion
This is the largest phase I pharmacokinetic trial yet performed in patients with CKD. The single-dose PK parameters t max and C max were consistent with previous observations in patients with normal renal function (healthy and diabetic). The association between CrCl and apparent clearance (Cl/F) of metformin was also similar to that observed in patients with normal renal function. However, Cl/F itself was much lower than in healthy patients and correspondingly steady-state minimum concentrations implied by our popPK model were higher.
Model-based steady-state concentrations appeared to fit the data well among a group of patients with high CrCl (median CrCl 41 mL/ min), but not among a group with low CrCl (median CrCl 24 mL/ min), suggesting that the first-order compartment model with absorption in a peripheral compartment breaks down as CrCl declines. We were probably able to detect this because, relative to previous studies, a much larger proportion of our study cohort (56%) had very low CrCl (<30 mL/min). Therefore, while the results suggest that 500-1000 mg per day could be taken by CKD-4 patients, metformin levels should be monitored regularly. We thank three anonymous reviewers for their insightful comments which led to meaningful improvements in the manuscript.
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